SLAS Discovery
Scope & Guideline
Shaping the Future of Biochemistry and Biotechnology
Introduction
Aims and Scopes
- High-Throughput Screening (HTS):
The journal extensively covers the development and optimization of high-throughput screening methodologies for drug discovery, enabling rapid evaluation of large compound libraries against biological targets. - Cell-Based Assays and Imaging:
SLAS Discovery emphasizes the use of cell-based assays, including high-content imaging and 3D cell cultures, to better mimic in vivo conditions and enhance the relevance of screening results. - Target Identification and Validation:
Research published in the journal often focuses on novel strategies for target identification and validation, including the application of proteomics and genomics to discover new drug targets. - Automation and Robotics in Drug Discovery:
The journal highlights advancements in automation and robotics that facilitate efficient assay development and compound screening, improving reproducibility and data quality in drug discovery. - Phenotypic Screening:
SLAS Discovery also explores phenotypic screening approaches that assess biological responses to compounds in cellular models, offering insights into complex drug action mechanisms. - Emerging Technologies:
The journal is dedicated to showcasing emerging technologies such as artificial intelligence (AI) and machine learning (ML) in drug discovery, aiming to enhance data analysis and predictive capabilities.
Trending and Emerging
- COVID-19 Therapeutics:
A significant number of recent publications are dedicated to discovering and validating therapeutics for COVID-19, reflecting the urgent need for effective treatments and the journal's responsiveness to global health challenges. - 3D Cell Culture and Organoids:
There is a growing trend towards the use of 3D cell culture systems and organoids, which provide more accurate representations of human tissues, enhancing drug screening and development processes. - Artificial Intelligence and Machine Learning:
The integration of AI and machine learning techniques into drug discovery processes is on the rise, with studies focusing on data mining, predictive modeling, and automated analysis to streamline hit identification. - Targeted Protein Degradation:
Research on targeted protein degradation, particularly using PROTACs (Proteolysis Targeting Chimeras), is emerging as a significant area of interest, offering new strategies for drug discovery against challenging targets. - Synergistic Drug Combinations:
There is an increasing focus on identifying synergistic drug combinations to enhance therapeutic efficacy, particularly in cancer treatment, which reflects a shift towards personalized medicine approaches.
Declining or Waning
- Traditional Biochemical Assays:
There is a noticeable decline in publications focusing solely on traditional biochemical assays, as the field moves towards more complex and physiologically relevant models. - Single-Dimensional Drug Screening:
Research centered around single-dimensional drug screening methods is waning, with a shift towards more integrated and multi-parametric approaches that provide a broader understanding of drug effects. - Basic Pharmacology Studies:
Basic pharmacology studies that do not incorporate advanced technologies or high-throughput capabilities appear to be less frequent, as there is a growing emphasis on translational research and clinical relevance. - In Vitro Models Lacking Complexity:
The use of simplistic in vitro models is decreasing, as researchers prioritize more complex systems that better replicate human physiology, such as organoids and multi-cellular models. - Focus on Established Targets:
There is a reduction in studies targeting well-characterized pathways or proteins, as the field increasingly seeks novel targets and mechanisms of action to overcome drug resistance.
Similar Journals
ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES
Empowering Insights in Assay Technologies and TherapeuticsASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.
CELL BIOCHEMISTRY AND BIOPHYSICS
Catalyzing Discoveries in Cell Biochemistry and BiophysicsCELL BIOCHEMISTRY AND BIOPHYSICS is a distinguished journal published by HUMANA PRESS INC, focusing on critical advancements in the fields of biochemistry, biophysics, and cell biology. Since its establishment, the journal has provided a robust platform for the dissemination of cutting-edge research, covering diverse aspects of cellular biochemistry and the physical principles that underlie biological systems. With an emphasis on interdisciplinary studies, the journal aims to facilitate knowledge exchange among researchers, professionals, and students from various scientific backgrounds. As reflected in its 2023 category rankings, it holds a respectable position in Q3 for Biochemistry and Cell Biology, and Q2 for both Biophysics and Medicine (miscellaneous), indicating its significant contribution to these fields. Although it operates under a subscription model, the journal's commitment to maintaining high publication standards ensures that only impactful studies are shared with its audience. With a range of articles spanning theoretical insights to practical applications, CELL BIOCHEMISTRY AND BIOPHYSICS is an essential resource for those aiming to stay at the forefront of biochemical and biophysical research.
NATURE REVIEWS DRUG DISCOVERY
Advancing the frontiers of pharmaceutical innovation.Nature Reviews Drug Discovery, published by Nature Portfolio, is a premier academic journal dedicated to the field of drug discovery. Since its inception in 2002, this journal has become an essential resource for researchers, professionals, and students, providing high-quality, peer-reviewed articles that present the latest advancements and insights into the complex landscape of pharmaceutical development. With an impressive impact factor placing it in the Q1 category across multiple disciplines, including Drug Discovery and Pharmacology, it continues to lead the way in pharmacological research, evidenced by its top ranks in Scopus among peers. Although it is not an open-access publication, the journal remains a vital tool for those looking to stay abreast of emerging trends and innovations in drug research. For more details about their submission guidelines and access options, visit the official journal website.
Drug Target Insights
Catalyzing Breakthroughs in Pharmaceutical Sciences.Drug Target Insights is a prestigious peer-reviewed journal published by ABOUTSCIENCE SRL, catering to the dynamic field of pharmacology and medicinal biochemistry. With an Open Access policy since 2006, the journal aims to promote the dissemination of cutting-edge research and innovations that target drug discovery and therapeutic developments. Based in Milan, Italy, it boasts a notable impact within its research community, achieving a Q3 classification in the categories of Clinical Biochemistry and Medical Pharmacology in 2023, alongside a robust performance in the Q2 category for Pharmacology, Toxicology, and Pharmaceutics. The journal serves as a vital platform for researchers, professionals, and students seeking to advance their understanding of drug delivery systems, therapeutic targets, and pharmacodynamics. With a commitment to enhancing global access to crucial research findings, Drug Target Insights stands out as an essential resource for those engaged in the ever-evolving landscape of pharmaceutical sciences.
Journal of Cheminformatics
Transforming data into discovery in cheminformatics.Journal of Cheminformatics, published by BMC, is a premier open-access journal that has been a cornerstone of cheminformatics research since its inception in 2009. With an ISSN of 1758-2946, this journal operates from the heart of the United Kingdom, providing a dynamic platform for disseminating high-quality, peer-reviewed articles that explore the integration of computer science with chemistry. The journal proudly stands in the prestigious Q1 category across multiple disciplines, including Computer Graphics, Computer-Aided Design, and Library and Information Sciences, showcasing its exceptional impact in the fields of cheminformatics and computational chemistry. Additionally, it ranks impressively in various Scopus categories, with notable placements such as #7 in Library and Information Sciences and #15 in Physical and Theoretical Chemistry, demonstrating its significance to the academic community. As a leader in open-access publishing, the Journal of Cheminformatics ensures that cutting-edge research and innovations are freely accessible to researchers, professionals, and students alike, fostering collaboration and advancement in this rapidly evolving field.
Expert Opinion on Drug Discovery
Driving Innovation in Drug DevelopmentExpert Opinion on Drug Discovery, published by Taylor & Francis Ltd, is a premier journal dedicated to the rapidly evolving field of drug development and innovation. With a strong emphasis on the integration of multidisciplinary approaches in pharmacology and toxicology, the journal has established itself as an invaluable resource for researchers, professionals, and students alike. Its impressive impact factor and classification as a Q1 journal in drug discovery, alongside its high Scopus ranking (Rank #20/157, Percentile 87th), underscore its significance within the academic community. Spanning from 2006 to 2024, Expert Opinion on Drug Discovery features a wide range of expert reviews and opinion articles that provide insights into the latest trends and breakthroughs in drug discovery, fostering collaboration and knowledge exchange. While the journal is not open access, it plays a critical role in shaping the future of drug development, making it an essential platform for those seeking to deepen their understanding of this dynamic field.
Future Medicinal Chemistry
Exploring innovative solutions in medicinal chemistry.Future Medicinal Chemistry is a premier journal dedicated to the rapidly evolving fields of drug discovery, pharmacology, and molecular medicine. Published by Newlands Press Ltd in the United Kingdom, this journal has garnered significant attention within the academic community, evidenced by its 2023 category rankings in Scopus, placing it in the Q2 quartile for Drug Discovery and the Q3 quartiles for both Molecular Medicine and Pharmacology. With an ISSN of 1756-8919 and an E-ISSN of 1756-8927, Future Medicinal Chemistry has been a cornerstone of scholarly discourse since its inception in 2009, continuously contributing to the advancement of knowledge and discussion in medicinal chemistry. The journal is committed to publishing high-quality, peer-reviewed research that addresses the challenges and innovations in drug development and therapeutic strategies, making it an essential resource for researchers, professionals, and students seeking to stay at the forefront of these critical fields. Engage with the latest findings and methodologies that shape the future of medicine by exploring the wealth of information offered within Future Medicinal Chemistry.
DRUG DISCOVERY TODAY
Pioneering Insights in Pharmacology and Drug DevelopmentDRUG DISCOVERY TODAY is a premier journal published by Elsevier Science Ltd, providing a vital platform for researchers, professionals, and students dedicated to the fields of drug discovery and pharmacology. With the ISSN 1359-6446 and E-ISSN 1878-5832, this esteemed journal has positioned itself at the forefront of scientific literature since its inception in 1996, boasting an impressive convergence set to last until 2024. Recognized for its rigorous peer-review process and high-quality publications, DRUG DISCOVERY TODAY attained a prestigious Q1 ranking in both Drug Discovery and Pharmacology categories for 2023, reflecting its significant impact and relevance in the field. With Scopus rankings placing it within the top percentile, at ranks #9 in Drug Discovery and #17 in Pharmacology out of over 300 journals, this journal serves as a crucial resource for the latest advancements and innovations in drug development. Although it does not offer Open Access, its comprehensive scope encompasses the most recent research, reviews, and insights, making DRUG DISCOVERY TODAY an essential read for anyone seeking to advance their knowledge and practice in pharmaceutical sciences.
CURRENT DRUG TARGETS
Transforming Drug Targets into Therapeutic TriumphsCURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.
COMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING
Elevating Drug Development Through Rigorous ResearchCOMBINATORIAL CHEMISTRY & HIGH THROUGHPUT SCREENING is an esteemed journal published by Bentham Science Publishers Ltd, focusing on the rapidly evolving fields of combinatorial chemistry and high-throughput screening. With ISSN 1386-2073 and E-ISSN 1875-5402, this journal provides a critical platform for researchers, professionals, and students engaged in the development and application of novel methodologies aimed at drug discovery and organic chemistry. Since its inception in 1998, the journal has consistently contributed valuable insights, achieving a respectable 2023 Category Quartile Ranking of Q3 across relevant categories including Computer Science Applications, Drug Discovery, and Organic Chemistry. Although it does not currently provide open access options, its rigorous peer-review process and commitment to scientific excellence enhance its reputation in the academic community. Researchers can leverage this journal's findings to stay at the forefront of advancements in their fields, making it an essential resource for anyone dedicated to innovation in chemistry and related disciplines.